There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viracta Therapeutics (VIRX – Research Report), Cidara Therapeutics (CDTX – Research Report) and OncoCyte (OCX – Research Report) with bullish sentiments.
Viracta Therapeutics (VIRX)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Viracta Therapeutics, with a price target of $35.00. The company’s shares closed last Wednesday at $2.04, close to its 52-week low of $2.03.
According to TipRanks.com, Burns has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viracta Therapeutics with a $20.33 average price target, representing a 783.9% upside. In a report issued on May 10, RBC Capital also maintained a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
Cidara Therapeutics (CDTX)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Cidara Therapeutics today and set a price target of $6.00. The company’s shares closed last Wednesday at $0.59, close to its 52-week low of $0.57.
According to TipRanks.com, Arce is a 4-star analyst with an average return of
Currently, the analyst consensus on Cidara Therapeutics is a Strong Buy with an average price target of $5.00.
OncoCyte (OCX)
In a report released today, Michael Matson from Needham maintained a Buy rating on OncoCyte, with a price target of $2.25. The company’s shares closed last Wednesday at $1.13, close to its 52-week low of $1.09.
According to TipRanks.com, Matson is a 3-star analyst with an average return of
OncoCyte has an analyst consensus of Strong Buy, with a price target consensus of $3.51, representing a 210.6% upside. In a report released yesterday, BTIG also reiterated a Buy rating on the stock with a $4.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VIRX:
- H.C. Wainwright Thinks Janux Therapeutics Inc’s Stock is Going to Recover
- Needham Thinks ACV Auctions’ Stock is Going to Recover
- H.C. Wainwright Reiterates a Buy Rating on BELLUS Health (BLU)
- H.C. Wainwright Thinks BioCardia’s Stock is Going to Recover
- Savara (SVRA) Gets a Buy Rating from H.C. Wainwright
